<td class= Dadun
   (New user)
Help  | Contact  |  Castellano English  

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Oncología > Terapia celular > DA - CIMA - Oncología - Terapia celular - Artículos de Revista >

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study
Authors: Mateos, M.V. (María Victoria)
Hernandez, J.M. (J. M.)
Hernandez, M.T. (M. T.)
Gutierrez, N.C. (N. C.)
Palomera, L. (Luis)
Fuertes, M. (M.)
Diaz-Mediavilla, J. (J.)
Lahuerta, J.J. (Juan J.)
Rubia, J. (J.) de la
Terol, M.J. (María José)
Sureda, A. (Anna)
Bargay, J. (J.)
Ribas, P. (Paz)
Arriba, F. (F.) de
Alegre, A. (A.)
Oriol, A. (Albert)
Carreras, D. (D.)
Garcia-Laraña, J. (J.)
Garcia-Sanz, R. (R.)
Blade, J. (J.)
Prosper, F. (Felipe)
Mateo, G. (Gemma)
Esseltine, D.L. (D. L.)
Velde, H. (Helgi) van de
San-Miguel, J.F. (Jesús F.)
Keywords: Materias Investigacion::Ciencias de la Salud
Issue Date: 2006
Publisher: American Society of Hematology
ISSN: 0006-4971
Citation: Mateos, M. V., Hernández, J. M., Hernández, M. T., Gutiérrez, N. C. et al. Blood 2006; 108 (7): 2165-2172
Standard first-line treatment for elderly multiple myeloma (MM) patients ineligible for stem cell transplantation is melphalan plus prednisone (MP). However, complete responses (CRs) are rare. Bortezomib is active in patients with relapsed MM, including elderly patients. This phase 1/2 trial in 60 untreated MM patients aged at least 65 years (half older than 75 years) was designed to determine dosing, safety, and efficacy of bortezomib plus MP(VMP). VMP response rate was 89%, including 32% immunofixation-negative CRs, of whom half of the IF– CR patients analyzed achieved immunophenotypic remission (no detectable plasma cells at 10 4 to 10 5 sensitivity). VMP appeared to overcome the poor prognosis conferred by retinoblastoma gene deletion and IgH translocations. Results compare favorably with our historical control data for MP—notably, response rate (89% versus 42%), event-free survival at 16 months (83% versus 51%), and survival at 16 months (90% versus 62%). Side effects were predictable and manageable; principal toxicities were hematologic, gastrointestinal, and peripheral neuropathy and were more evident during early cycles and in patients aged 75 years or more. In conclusion, in elderly patients ineligible for transplantation, the combination of bortezomib plus MP appears significantly superior to MP, producing very high CR rates, including immunophenotypic CRs, even in patients with poor prognostic features.
Permanent link:
Appears in Collections:DA - CIMA - Oncología - Síndromes mieloproliferativos - Artículos de Revista
DA - CIMA - Oncología - Terapia celular - Artículos de Revista
DA - CUN - Área de Terapia Celular - Artículos de revista
DA - Medicina - Hematología - Artículos de revista

Files in This Item:

There are no files associated with this item.

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.